TEL AVIV, Israel, June 9, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will be a featured speaker and presenter at the 2014 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) 2014 Annual Meeting, being held June 16-19, 2014 at the Westin Diplomat Hotel in Hollywood, Florida.
| Oral Presentation | |
| Date: | Monday, June 16, 2014 |
| Session: | Pharmaceutical Pipelines |
| Time: | 2:00pm Eastern |
| Location: | Grand Ballroom |
| Poster Presentation | |
| Date: | Tuesday, June 17, 2014 |
| Time: | 11:15am – 1:00pm Eastern |
| Title: | Metadoxine Extended Release (MDX): |
| A Novel Drug Candidate for the Treatment of ADHD & Other Cognitive Disorders | |
| Location: | Poster Board #P-8, Regency Ballroom |
Dr. Rubin will also be presenting a corporate overview of Alcobra at the BIO International Convention being held at the San Diego Convention Center in San Diego, California.
| Company Presentation | |
| Date: | Thursday, June 26, 2014 |
| Time: | 11:45am Pacific |
| Location: | San Diego Convention Center, Pacific Beach Room |
About the ASCP Annual Meeting (f/k/a the New Clinical Drug Evaluation Unit (NCDEU))
The ASCP Annual Meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees. ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented. More information about the history and purpose of the ASCP Annual Meeting is available at the Annual Meeting Overview.
About the BIO International Convention
The Biotechnology Industry Organization (BIO) hosts the BIO International Convention. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder, and is enrolling patients in a Phase III study for this indication in adults. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.